Skip to content

EBIT at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$54.12M-17.7%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
Scholar Rock logo
Scholar RockSRRK
-$102.02M-32.3%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$73.23M+15.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.27B+153%
Enterprise value$2.69B+228%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s EBIT?
Dyne Therapeutics, Inc. (DYN) reported EBIT of -$125.28M in Q1 2026.
How has Dyne Therapeutics, Inc.'s EBIT changed year-over-year?
Dyne Therapeutics, Inc.'s EBIT decreased by 2.4% year-over-year, from -$122.37M to -$125.28M.
What is the long-term trend for Dyne Therapeutics, Inc.'s EBIT?
Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s EBIT has grown at a 32.9% compound annual growth rate (CAGR), from -$150.03M to -$468.18M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.